Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Yamamura, Takashi; Kleiter, Ingo; Fujihara, Kazuo; Palace, Jacqueline; Greenberg, Benjamin; Zakrzewska‐Pniewska, Beata; Patti, Francesco; Tsai, Ching‐Piao; Saiz, Albert; Yamazaki, Hayato; Kawata, Yuichi; Wright, Pádraig; Sèze, de

doi:10.1056/nejmoa1901747

Public

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Published in New England Journal of Medicine • Nov 27, 2019

Authors:

Takashi Yamamura

Ingo Kleiter

Kazuo Fujihara

Abstract

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with autoantibodies to anti-aquaporin-4 (AQP4-IgG) in approximately two thirds of patients. Interleukin-6 is involved in the pathogenesis of the disorder. Satralizumab ...

Subject

Medicine

Neuromyelitis optica

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!